Pericot I, Montalban X
Unidad de Neuroinmunología Clínica, Escuela de Enfermería, Hospital Universitario Vall d'Hebron Barcelona, Spain.
Neurologia. 2003 Jul-Aug;18(6):318-23.
Mitoxantrone is an antineoplastic agent that exerts a potent immunosuppresive effect, including suppression of B cell immunity and reduction of T cell numbers. Clinical trials have shown that mitoxantrone has a statistically significant impact on reduction of relapse rate and delays disability progression in patients with relapsing remitting (RR) multiple sclerosis (MS) or secondary progressive (SP) MS. Treatment is well tolerated, but the risk of cardiotoxicity at higher cumulative doses is likely to limit the duration of treatment. The maximum cumulative dose recommended is 140 mg/m2. In 2000, the FDA (Food and Drug Administration) approved the use of mitoxantrone for the treatment of active RRMS, SPMS and progressing relapsing (PR) MS.
米托蒽醌是一种抗肿瘤药物，具有强大的免疫抑制作用，包括抑制B细胞免疫和减少T细胞数量。临床试验表明，米托蒽醌在降低复发缓解型（RR）多发性硬化症（MS）或继发进展型（SP）MS患者的复发率和延缓残疾进展方面具有统计学上的显著影响。该治疗耐受性良好，但较高累积剂量时的心脏毒性风险可能会限制治疗持续时间。推荐的最大累积剂量为140mg/m²。2000年，美国食品药品监督管理局（FDA）批准米托蒽醌用于治疗活动性RRMS、SPMS和进展性复发型（PR）MS。
